Stifel Cuts Price target on Argos Therapeutics (ARGS) Following 4Q15 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- S&P 500, Nasdaq set for lower open after inflation data; Nvidia results awaited
- Oil drops to more than two-week low on hopes of Hormuz reopening
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Argos Therapeutics (ARGS) Tops Q4 EPS by 4c
March 29, 2016 4:35 PM EDTArgos Therapeutics (NASDAQ: ARGS) reported Q4 EPS of ($0.84), $0.04 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $73.8 thousand versus the consensus estimate of $720 thousand.
"In the past year we have achieved a number of important milestones, both from a clinical and a corporate perspective, said Jeff Abbey, president and chief executive officer. In July, we successfully completed enrollment of our Phase 3 ADAPT trial of AGS-003 in metastatic renal cell carcinoma. The ADAPT trial also successfully navigated two data analyses, in June and December, by... More
